Loading clinical trials...
Loading clinical trials...
Mauritius is located in the southern Indian Ocean with a population of 1.3 million in 2023. Mauritius is a multiethnic nation with 68% South Asian, 27% African (Creole), 3% Chinese and 2% Franco Mauritians. Seven population-based cross-sectional surveys using standardised protocols were conducted between 1987 and 2021). The participation rate has been over 85% in each survey. At each survey, participants were interviewed about living conditions, lifestyle and health, and anthropometry and blood pressure were measured. Biochemistry including lipids and an oral glucose tolerance test (OGTT) were performed Electrocardiograms (ECG) were recorded in participants aged 35 years and older. Previous participants were followed up in 2007 and 92% were successfully traced. Studies with identical methodology have been performed on the neighbouring island Rodrigues where the majority of the population are Creoles.
Mauritius and Rodrigues are islands in the south-eastern part of the Indian Ocean. Major changes in lifestyle have been seen during the last fifty years, including less physical activity and introduction of a westernised diet. In parallel, the disease panorama has changed from high infant mortality and infectious diseases to lifestyle-related diseases such as cardiovascular disease and type 2 diabetes. The population in Mauritius are descendants to immigrants from South Asia, Africa and China, i.e., approximately 60% of the world population are represented. Mauritius is probably the only developing country that has followed the development of non-communicable diseases (NCD) and associated risk factors over a long time-period and continues to do so. In the mid-eighties, the Mauritian government initiated a study on the prevalence of type 2 diabetes and cardiovascular disease, in collaboration with WHO and international experts. Altogether seven population-based surveys have been performed between 1987 and 2021, and approximately 39 000 (!) examinations have been recorded. The intention is to repeat the survey every fifth year. The ethnicities of the participants have been 71% South Asians (India/Pakistan), 24% Creoles (Africa) and 5% Chinese, which reflects well the ethnical distribution of the population. Previous participants were followed up in 2007 and 92% were successfully traced. Studies have also been performed on the neighbouring island Rodrigues where the majority of the population are Creoles. During the follow-up survey in 2010, 97% of the 9 700 participants were traced. At each survey, information was given and an individual consent form was signed. See attached the local (in Mauritius) ethical approval and consent form from the Mauritius survey 2021. At each survey, participants were interviewed about living conditions, lifestyle and health, and anthropometry and blood pressure were measured. Biochemistry including lipids and an oral glucose tolerance test (OGTT) were performed Altogether approximately 28 000 electrocardiograms (ECG) were recorded in participants aged 35 years and older, all of which have been coded in Kaunas, Lithuania for signs of ischemic heart disease (Minnesota criteria) and myocardial hypertrophy. The Mauritius NCD study was initially administrated by the International Diabetes Institute in Melbourne, Australia under the leadership of Professor Paul Zimmet together with Professor Jaakko Tuomilehto (Finland) and Professor George Alberti (United Kingdom). Today, the study is administrated and financed by the Ministry of health in Mauritius under the leadership of Doctor Sudhir Kowlessur. Professor Stefan Söderberg at the Department of Public Health and Clinical Medicine, Umeå University, Sweden was introduced to the Mauritius NCD study during his postdoc (2001-2002) in Professor Zimmet's research team at IDI in Melbourne. Söderberg has since then continued to assist in the performance of the surveys and to analyse data. Today, Umeå university and the Department of Public Health and Clinical medicine have been granted the privilege to curate and analyse data generated in the Mauritius and Rodrigues NCD study. Each survey has been evaluated and approved by the local ethics committee in Mauritius (see attached the approval from 2021). Analysing data in Sweden has been approved by the Swedish Ethical Authority (2023-07199-01).
Age
25 - 74 years
Sex
ALL
Healthy Volunteers
Yes
Port Louis, Mauritius
Start Date
April 5, 1987
Primary Completion Date
November 23, 2021
Completion Date
December 31, 2050
Last Updated
July 17, 2025
39,082
ACTUAL participants
Lead Sponsor
Umeå University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07083401